Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS: CFZ533 in Sjögren's Syndrome
NCT03905525Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial of iscalimab in Sjögren's syndrome (6 cohorts), sponsored by Novartis. Primary endpoints: EULAR Sjögren Syndrome Disease Activity Index at 24 weeks and EULAR Sjögren Syndrome Patient Reported Index at 24 weeks. Started Oct 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT03905525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905525.